M. Avenel‐Audran

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

The Lymphoid Variant of Hypereosinophilic Syndrome

Guillaume Lefèvre, Marie‐Christine Copin, D. Staumont‐Sallé et al. · Medicine · 2014 · 122 citations · Full text

Life Sciences, Immunology, Pathology +14

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 95 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score ( <scp>ABSIS</scp> ) and Pemphigus Disease Area Index ( <scp>PDAI</scp> ) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus

C. Boulard, S. Duvert Lehembre, C. Picard‐Dahan et al. · British Journal of Dermatology · 2016 · 92 citations · Full text

Medicine, Dermatology, Autoimmunity +16

New‐onset vitiligo and progression of pre‐existing vitiligo during treatment with biological agents in chronic inflammatory diseases

L. Méry‐Bossard, K. Bagny, G. Chaby et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 86 citations

Medicine, Dermatology, Immunology +15